\$.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 30523/105

In re patent application of

Henryk LUBON et al.

Serial No. 07/943,246

Group Art Unit: 1804

Filed: September 10, 1992

Examiner: Dubrule

For: EXPRESSION OF ACTIVE HUMAN PROTEIN C IN MAMMARY TISSUE OF

TRANSGENIC ANIMALS USING A LONG WAP PROMOTER

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Honorable Assistant Secretary and Commissioner of Patents and Trademarks Washington, D.C. 20231 Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states:

- 1. that the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter; and
- 2. that the content of the attached papers and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Januar 25, 1993

bate

Respectfully submitted,

Stephen A. Bent Reg. No. 29,768

FOLEY & LARDNER
P. O. Box 299
Alexandria, Virginia 22313
(703) 836-9300

FOLEY & LARDNER
PO BOX 299
ALEXANDRIA, VA 22313-0299

JAN 7 1993

HENRYK LUBON SEPTEMBER 10, 199 07/943,246

	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES MAILED: JAN - 5
4/93	This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or arcino acid sequences set forth in 37 CFR § 1.121(aX1) and (aX2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.82 as follows:
8	1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's stiention is directed to these regulations, a copy of which is attached.
	2. This application does not conform exclusively to the requirements of \$6 1.821 through 1.825. The non-conforming material should be deleted. \$1.821(b).
22	3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
hiting	4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" opes not comply with the requirements of \$ 1.821 through 1.825 as follows:
)	a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically:
3	Db. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
J.	paragraph (b) of § 1.823. Specifically:
7	
	5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made so the sequence by use of a sequence identifier as required by § 1.821(d).
	6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by \$1.821(c).
	7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically:
	8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
	9. The amendment to or replacement of the paper and/or computer readable copies of the Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
·a :	10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer about form accompanied by a statement that the substitute data is identical to that originally lied. § 1.825(d). Specifically:
	[] 11. Other
۱ د ن د ع	FPLICANT IS OIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH O COMPLY WITH THE ABOVE REQUIREMENTS. Fallur to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by fling a petition accompanied by the extension fee under the provisions of CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A pay of this notice MUST be returned with your response.
	For N's 1801 A N. 120.3 Processing Division (103) 308 (100) 508 (1